The P-II (SAVANNAH) trial evaluates savolitinib + AstraZeneca’s Tagrisso in 294 EGFR-mutated NSCLC patients with MET-driven tumors, following disease progression on treatment with Tagrisso
At the data cut-off date of Aug 2022, the results from an analysis of 193 efficacy evaluable patients who received savolitinib (300mg, qd) + TAGRISSO (80mg, qd) showed improved response rates with increasing levels of MET aberration, ORR (32%), m-DoR (8.3mos.), m-PFS (5.3mos.). The results were consistent with the prior results from the (TATTON) exploratory study
Patients who exhibited higher cut-off MET abnormality levels, ORR was 49%, m-DoR (9.3mos.) & m-PFS (7.1mos.). The safety profile was consistent with the known profiles of the combination & each treatment alone
Ref: HUTCHMED | Image: HUTCHMED
